These data clearly demonstrated that the COVID-19 patients’ sera had ADE potential for SARS-CoV-2 infection in vitro and also indicated that ADE antibodies had the ability to counteract neutralizing activity in the presence of FcγR on the target cell surface or C1q in the culture medium. Here, FCGR2A is linked to COVID-19.